Israeli biotech Gamida Cell published positive results in its Phase I/II trial of NiCord, for the treatment of Sickle-Cell Disease (SCD). All the patients that completed the trial were free of SCD symptoms.
http://www.globes.co.il/en/article-gamida-reports-positive-nicord-results-1001165382